Prediction of pathological complete response after neoadjuvant treatment in triple negative breast cancer: a single center experience

Abstract

Purpose: To identify clinicopathological factors associated with pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC).
Matherials and methods: A retrospective study of 51 women with stage I–III TNBC who received NAC between January 2019 and December 2024 at Antalya Training and Research Hospital. Binary logistic regression was used to determine independent predictors of pCR.
Results: The median age was 49 years (range: 28-79), and 28 patients (54.9%) achieved pCR. Patients aged ≥60 were significantly less likely to achieve pCR (OR: 0.22; 95% CI: 0.05-0.98; p=0.048*). No significant associations were found for carboplatin or pembrolizumab use.
Conclusion: This real-world cohort confirms that pCR rates are consistent with literature. Advanced age was a significant negative predictor, emphasizing the importance of personalized approaches in elderly patients.

Keywords

• Triple-negative breast cancer
• neoadjuvant treatment
• pathological complete response

Üçlü negatif meme kanserinde neoadjuvan tedavi sonrası patolojik tam yanıtın öngörülmesi: tek merkez deneyimi

Abstract

Amaç: Üçlü negatif meme kanseri (TNBC) hastalarında neoadjuvan kemoterapi (NAK) sonrası patolojik tam yanıt (pTY) ile ilişkili klinikopatolojik faktörleri belirlemektir.
Gereç ve yöntem: Ocak 2019 - Aralık 2024 tarihleri arasında Antalya Eğitim ve Araştırma Hastanesi'nde NAK almış evre I–III TNBC tanılı 51 kadın hastanın verileri retrospektif olarak incelendi. pTY'yi öngören bağımsız değişkenleri belirlemek amacıyla ikili lojistik regresyon analizi yapıldı.
Bulgular: Ortanca yaş 49 (28-79) idi ve 28 hastada (%54,9) pTY elde edildi. Yaş ≥60 olan hastalarda pTY elde etme olasılığı anlamlı şekilde düşüktü (OR: 0,22; %95 GA: 0,05-0,98; p=0,048*). Karboplatin ve pembrolizumab kullanımı ile pTY arasında istatistiksel olarak anlamlı ilişki bulunmadı.
Sonuç: Gerçek yaşam verilerine dayanan bu çalışmada, pTY oranı literatürle uyumluydu. Yaşlı hastalarda pTY oranının düşük olması, kişiselleştirilmiş tedavi yaklaşımlarının gerekliliğini vurgulamaktadır.

Keywords

• Üçlü negatif meme kanseri
• neoadjuvan tedavi
• patolojik tam yanıt

References

1. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016;13(11):674-690. doi:10.1038/nrclinonc.2016.66
2. Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430-2442. doi:10.1016/S0140-6736(16)32454-0
3. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275-1281. doi:10.1200/JCO.2007.14.4147
4. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [published correction appears in Lancet. 2019 Mar 9;393(10175):986. doi: 10.1016/S0140-6736(18)32772-7.]. Lancet. 2014;384(9938):164-172. doi:10.1016/S0140-6736(13)62422-8
5. Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29(7):1497-1508. doi:10.1093/annonc/mdy127
6. Schmid P, Cortes J, Dent R, et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651
7. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796-1804. doi:10.1200/JCO.2011.38.8595
8. Gass P, Lux MP, Rauh C, et al. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer. 2018;18(1):1051. doi:10.1186/s12885-018-4925-1

9. Verdial FC, Mamtani A, Pawloski KR, et al. The Effect of Age on Outcomes After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2022;29(6):3810-3819. doi:10.1245/s10434-022-11367-w
10. Krishnan J, Patel A, Roy AM, et al. Detrimental Impact of Chemotherapy Dose Reduction or Discontinuation in Early Stage Triple-Negative Breast Cancer Treated With Pembrolizumab and Neoadjuvant Chemotherapy: A Multicenter Experience. Clin Breast Cancer. 2024;24(8):e701-e711.e2. doi:10.1016/j.clbc.2024.08.005
11. Pawelec G, Derhovanessian E, Larbi A. Immunosenescence and cancer. Crit Rev Oncol Hematol. 2010;75(2):165-172. doi:10.1016/j.critrevonc.2010.06.012
12. Shepherd JH, Ballman K, Polley MC, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. J Clin Oncol. 2022;40(12):1323-1334. doi:10.1200/JCO.21.01506
13. Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer. 2019;19(1):1065. doi:10.1186/s12885-019-6253-5
14. Gianni L, Huang CS, Egle D, et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. Ann Oncol. 2022;33(5):534-543. doi:10.1016/j.annonc.2022.02.004